EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Price:
11.13 USD
-0.27%
Market Closed
Updated:
May 29, 2024
EyePoint Pharmaceuticals Inc
Total Liabilities
|
EyePoint Pharmaceuticals Inc
Total Liabilities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Total Liabilities
$79.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities
$101.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities
$82.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
16%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities
$128.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities
$65.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities
$51.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
See Also
What is EyePoint Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
79.3m
USD
79.3m
USD
Based on the financial report for Mar 31, 2024, EyePoint Pharmaceuticals Inc's Total Liabilities amounts to 79.3m USD.
What is EyePoint Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
26%
26%
Over the last year, the Total Liabilities growth was 4%. The average annual Total Liabilities growth rates for EyePoint Pharmaceuticals Inc have been 4% over the past three years , 5% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
